Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

52P - Real-world efficacy and safety of trastuzumab deruxtecan in heavily pre-treated HER2-low metastatic breast cancer with distinct IHC statuses: Evidence from a Chinese population

Date

07 Dec 2024

Session

Poster Display session

Presenters

Song Wu

Citation

Annals of Oncology (2024) 35 (suppl_4): S1418-S1425. 10.1016/annonc/annonc1685

Authors

S. Wu, J.B. Li, L. Bian, S. Zhang, S. Zhang, T. Wang, Z. Jiang

Author affiliations

  • Department Of Breast Oncology, The Fifth Medical Centre of Chinese PLA General Hospital, 100071 - Beijing/CN

Resources

This content is available to ESMO members and event participants.

Abstract 52P

Background

For trastuzumab deruxtecan (T-DXd) treatment in human epidermal growth factor receptor 2 (HER2)-low metastatic breast cancer (MBC), there are currently no real-world data to assess the efficacy differences between the immunohistochemistry (IHC) 1+ and 2+ subgroups. This study thus investigated the effectiveness and safety of T-DXd in a real-world Chinese population with HER2-low MBC and compared the outcomes between these two categories.

Methods

This single-centre, retrospective study enrolled patients with HER2-low MBC who received T-DXd between June 2022 and December 2023. The primary study endpoint was progression-free survival (PFS). Objective response rate (ORR) and clinical benefit rate (CBR) were also reported. Safety was monitored by documenting adverse events (AEs).

Results

Among the 70 eligible patients, 37 (52.9%) had IHC 1+ and 33 (47.1%) had IHC 2+. Thirty-three (47.1%) patients received ≥ 3 lines of chemotherapy before T-DXd treatment. The median initial T-DXd dose was 4.6 mg/kg (interquartile range: 3.7-5.3) every three weeks. The median PFS for the IHC 1+ and 2+ groups was 3 and 5 months, respectively (adjusted hazard ratio [HR]: 0.51, 95% confidence interval [CI]: 0.28-0.95, p = 0.034). The ORR was 16.2% and 27.3%, respectively, while the CBR was 24.3% and 36.4%, respectively. Patients who received ≥ 3 lines of previous chemotherapy had a shorter PFS compared to those who received ≤ 2 lines (median PFS: 3 vs. 5 months, adjusted HR: 1.99, 95% CI: 1.10-3.58, p = 0.022). Patients who received higher initial T-DXd doses demonstrated a better prognosis than those who received lower doses (adjusted HR: 0.64 per mg/kg, 95% CI: 0.45-0.89, p = 0.009). Nausea was the most prevalent AE, occurring in 30 (42.9%) participants, while the most common grade 3-4 AEs were neutropenia, anemia, and leukopenia (each 7.1%). No significant differences in toxicity were observed between the IHC 1+ and 2+ groups.

Conclusions

Compared to patients with IHC 1+, those with IHC 2+ are more likely to benefit from T-DXd treatment. Intensive previous chemotherapy and insufficient initial T-DXd doses might negatively impact the efficacy of T-DXd.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.